ACAD
ACADIA Pharmaceuticals Inc. NASDAQ Listed May 27, 2004$22.56
Mkt Cap $3.9B
52w Low $14.68
57.6% of range
52w High $28.35
50d MA $22.04
200d MA $23.75
P/E (TTM)
9.5x
EV/EBITDA
31.7x
P/B
3.0x
Debt/Equity
0.0x
ROE
31.9%
P/FCF
43.0x
RSI (14)
—
ATR (14)
—
Beta
0.83
50d MA
$22.04
200d MA
$23.75
Avg Volume
2.1M
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
12830 El Camino Real · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.04 | 0.02 | -50.0% | 21.48 | +1.9% | +5.0% | — | — | — | — | — |
| Feb 25, 2026 | AMC | 0.14 | 1.60 | +1067.9% | 24.97 | -5.3% | -1.3% | -1.6% | -8.7% | -9.9% | -6.3% | — |
| Nov 5, 2025 | AMC | 0.14 | 0.26 | +85.7% | 22.33 | +5.6% | -3.0% | +1.1% | -0.6% | +6.2% | +8.1% | — |
| Aug 6, 2025 | AMC | 0.14 | 0.16 | +14.3% | 23.80 | +1.1% | +2.5% | +3.4% | +4.3% | +6.9% | +5.6% | — |
| May 7, 2025 | AMC | 0.10 | 0.11 | +10.0% | 14.81 | -0.6% | +14.3% | +17.8% | +18.3% | +16.1% | +15.9% | — |
| Feb 26, 2025 | AMC | 0.13 | 0.17 | +30.8% | 19.00 | +2.3% | +1.8% | +3.2% | -4.4% | -3.9% | -4.8% | — |
| Nov 6, 2024 | AMC | 0.14 | 0.20 | +42.9% | 15.79 | -0.6% | +8.9% | +11.8% | +15.7% | +13.6% | +11.4% | — |
| Aug 6, 2024 | AMC | 0.18 | 0.20 | +11.1% | 18.85 | -18.3% | -19.5% | -16.6% | -17.1% | -18.9% | -16.6% | — |
| May 8, 2024 | AMC | 0.05 | 0.10 | +100.0% | 17.13 | +2.2% | -11.2% | -11.0% | -11.4% | -13.3% | -11.7% | — |
| Feb 27, 2024 | AMC | 0.30 | 0.28 | -6.7% | 26.36 | -6.5% | -9.9% | -11.8% | -8.9% | -9.9% | -9.7% | — |
| Nov 2, 2023 | AMC | -0.43 | -0.40 | +7.0% | 22.99 | +4.4% | +4.7% | +4.3% | +2.2% | +0.9% | -4.3% | — |
| Aug 2, 2023 | AMC | -0.12 | 0.01 | +108.3% | 29.20 | -4.2% | -6.8% | -6.9% | -8.2% | -8.5% | -8.9% | — |
| May 8, 2023 | AMC | -0.21 | -0.27 | -28.6% | 21.55 | +0.2% | -0.6% | +0.5% | -1.0% | -0.4% | +2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | BofA Securities | Upgrade | Neutral → Buy | — | $20.96 | $21.40 | +2.1% | +5.0% | +2.4% | -1.0% | +0.5% | +6.2% |
| Mar 4 | JP Morgan | Maintains | Overweight → Overweight | — | $22.50 | $23.05 | +2.4% | +4.0% | -0.4% | -1.5% | +0.4% | +0.2% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $24.97 | $23.64 | -5.3% | -1.3% | -1.6% | -8.7% | -9.9% | -6.3% |
| Feb 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $24.97 | $23.64 | -5.3% | -1.3% | -1.6% | -8.7% | -9.9% | -6.3% |
| Feb 26 | Stifel | Maintains | Hold → Hold | — | $24.97 | $23.64 | -5.3% | -1.3% | -1.6% | -8.7% | -9.9% | -6.3% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $24.97 | $23.64 | -5.3% | -1.3% | -1.6% | -8.7% | -9.9% | -6.3% |
| Feb 23 | Mizuho | Upgrade | Neutral → Outperform | — | $23.99 | $24.78 | +3.3% | +3.1% | +2.5% | +4.1% | +2.7% | +2.4% |
| Feb 6 | Oppenheimer | Maintains | Perform → Perform | — | $23.46 | $24.04 | +2.5% | +0.4% | -1.0% | -3.2% | -4.2% | -7.9% |
| Feb 3 | RBC Capital | Maintains | Outperform → Outperform | — | $26.13 | $25.69 | -1.7% | -5.2% | -7.3% | -10.2% | -9.8% | -11.1% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.13 | $25.69 | -1.7% | -5.2% | -7.3% | -10.2% | -9.8% | -11.1% |
| Feb 3 | Citizens | Maintains | Market Outperform → Market Outperform | — | $26.13 | $25.69 | -1.7% | -5.2% | -7.3% | -10.2% | -9.8% | -11.1% |
| Jan 6 | UBS | Maintains | Buy → Buy | — | $26.15 | $26.50 | +1.3% | +3.0% | +4.9% | +2.9% | +2.4% | +1.7% |
| Jan 6 | Citigroup | Maintains | Buy → Buy | — | $26.15 | $26.50 | +1.3% | +3.0% | +4.9% | +2.9% | +2.4% | +1.7% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.15 | $27.18 | +0.1% | +0.4% | -1.3% | -0.8% | -2.0% | +0.0% |
| Dec 11 | Stifel | Maintains | Hold → Hold | — | $26.81 | $26.67 | -0.5% | -0.5% | +1.3% | +1.7% | -0.0% | +0.4% |
| Dec 2 | Mizuho | Maintains | Neutral → Neutral | — | $24.85 | $25.24 | +1.6% | +2.3% | +4.1% | +6.8% | +10.4% | +7.7% |
| Nov 17 | JP Morgan | Maintains | Overweight → Overweight | — | $24.02 | $23.65 | -1.5% | -0.0% | -0.9% | -3.8% | -4.7% | -1.9% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $22.33 | $23.58 | +5.6% | -3.0% | +1.1% | -0.6% | +6.2% | +8.1% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $22.33 | $23.58 | +5.6% | -3.0% | +1.1% | -0.6% | +6.2% | +8.1% |
| Sep 29 | JP Morgan | Maintains | Overweight → Overweight | — | $21.05 | $21.27 | +1.0% | +1.3% | +1.4% | +0.9% | +1.6% | +3.6% |
| Sep 24 | Needham | Maintains | Buy → Buy | — | $23.60 | $20.82 | -11.8% | -9.9% | -10.1% | -10.8% | -9.7% | -9.6% |
| Sep 11 | TD Cowen | Maintains | Buy → Buy | — | $23.80 | $24.16 | +1.5% | +1.7% | -0.8% | +3.7% | +0.7% | +1.7% |
| Sep 9 | UBS | Maintains | Buy → Buy | — | $25.39 | $25.54 | +0.6% | -2.2% | -6.3% | -4.7% | -7.0% | -2.8% |
| Aug 8 | UBS | Maintains | Buy → Buy | — | $24.40 | $24.40 | +0.0% | +0.8% | +1.7% | +4.3% | +3.0% | +0.5% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $23.80 | $24.06 | +1.1% | +2.5% | +3.4% | +4.3% | +6.9% | +5.6% |
| Aug 7 | Goldman Sachs | Maintains | Sell → Sell | — | $23.80 | $24.06 | +1.1% | +2.5% | +3.4% | +4.3% | +6.9% | +5.6% |
| Aug 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $23.80 | $24.06 | +1.1% | +2.5% | +3.4% | +4.3% | +6.9% | +5.6% |
| Aug 7 | BofA Securities | Maintains | Neutral → Neutral | — | $23.80 | $24.06 | +1.1% | +2.5% | +3.4% | +4.3% | +6.9% | +5.6% |
| Aug 7 | Mizuho | Maintains | Neutral → Neutral | — | $23.80 | $24.06 | +1.1% | +2.5% | +3.4% | +4.3% | +6.9% | +5.6% |
| Jul 24 | JP Morgan | Maintains | Overweight → Overweight | — | $23.27 | $23.00 | -1.2% | -0.9% | -0.1% | -2.8% | -2.8% | +1.1% |
| Jun 27 | UBS | Maintains | Buy → Buy | — | $22.21 | $22.18 | -0.1% | -0.4% | -2.9% | -3.8% | -4.4% | -5.7% |
| Jun 26 | Oppenheimer | Maintains | Perform → Perform | — | $22.50 | $22.56 | +0.3% | -1.3% | -1.7% | -4.1% | -5.1% | -5.6% |
| Jun 26 | Needham | Maintains | Buy → Buy | — | $22.50 | $22.56 | +0.3% | -1.3% | -1.7% | -4.1% | -5.1% | -5.6% |
| Jun 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $22.50 | $22.56 | +0.3% | -1.3% | -1.7% | -4.1% | -5.1% | -5.6% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.50 | $22.56 | +0.3% | -1.3% | -1.7% | -4.1% | -5.1% | -5.6% |
| Jun 23 | RBC Capital | Maintains | Outperform → Outperform | — | $22.71 | $23.04 | +1.5% | -1.0% | -1.3% | -0.9% | -2.2% | -2.6% |
| Jun 6 | JP Morgan | Maintains | Overweight → Overweight | — | $21.34 | $21.53 | +0.9% | +3.0% | +4.5% | +4.0% | +4.5% | +1.9% |
| Jun 5 | BofA Securities | Maintains | Neutral → Neutral | — | $21.77 | $21.61 | -0.7% | -2.0% | +1.0% | +2.4% | +2.0% | +2.4% |
| May 21 | Deutsche Bank | Upgrade | Hold → Buy | — | $21.69 | $22.24 | +2.5% | +0.7% | -0.6% | +1.3% | +2.3% | +1.5% |
| May 20 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $21.99 | $21.85 | -0.6% | -1.4% | -0.6% | -2.0% | -0.0% | +0.9% |
| May 19 | RBC Capital | Maintains | Outperform → Outperform | — | $22.26 | $22.30 | +0.2% | -1.2% | -2.6% | -1.8% | -3.2% | -1.3% |
| May 19 | BMO Capital | Maintains | Outperform → Outperform | — | $22.26 | $22.30 | +0.2% | -1.2% | -2.6% | -1.8% | -3.2% | -1.3% |
| May 19 | Needham | Maintains | Buy → Buy | — | $22.26 | $22.30 | +0.2% | -1.2% | -2.6% | -1.8% | -3.2% | -1.3% |
| May 19 | Mizuho | Maintains | Neutral → Neutral | — | $22.26 | $22.30 | +0.2% | -1.2% | -2.6% | -1.8% | -3.2% | -1.3% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.26 | $22.30 | +0.2% | -1.2% | -2.6% | -1.8% | -3.2% | -1.3% |
| May 19 | Baird | Maintains | Outperform → Outperform | — | $22.26 | $22.30 | +0.2% | -1.2% | -2.6% | -1.8% | -3.2% | -1.3% |
| May 16 | JP Morgan | Maintains | Overweight → Overweight | — | $17.60 | $18.37 | +4.4% | +26.5% | +24.9% | +23.2% | +24.1% | +22.4% |
| May 8 | Deutsche Bank | Maintains | Hold → Hold | — | $14.81 | $14.72 | -0.6% | +14.3% | +17.8% | +18.3% | +16.1% | +15.9% |
| Apr 28 | UBS | Maintains | Buy → Buy | — | $14.73 | $14.80 | +0.5% | -0.5% | -2.0% | -0.9% | -1.1% | +1.2% |
| Apr 17 | BMO Capital | Maintains | Outperform → Outperform | — | $14.57 | $14.47 | -0.7% | +1.1% | -1.3% | -1.5% | +0.3% | +1.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,332 | $21.79 | $29K | 29,129 | -3.89% | — |
| May 4, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,506 | $21.79 | $76K | 66,145 | -3.89% | — |
8-K · 5.02
!!! Very High
ACADIA Pharmaceuticals Inc. -- 8-K 5.02: Executive Change
ACADIA Pharmaceuticals appointed Thompson as a director, potentially signaling new leadership perspective and governance strengthening for the biopharmaceutical company's board oversight.
May 1
8-K · 5.02
!!! Very High
Acadia Pharmaceuticals Inc. -- 8-K 5.02: Executive Change
Jonathan M. Poole has joined Acadia Pharmaceuticals' board as a Class II director, expanding the company's governance structure and potentially bringing new expertise to guide strategic decisions.
Mar 5
8-K
Acadia Pharmaceuticals Inc. -- 8-K Filing
Acadia Pharmaceuticals surpassed $1 billion in annual revenue for the first time in 2025, demonstrating strong operational growth and market success across its pharmaceutical portfolio.
Feb 25
Data updated apr 24, 2026 10:23am
· Source: massive.com